Climb Bio (NASDAQ:CLYM) Trading Up 10.1% – Here’s Why

Posted by Geri Gentry on Jun 8th, 2026

Climb Bio, Inc. (NASDAQ:CLYM – Get Free Report) was up 10.1% during mid-day trading on Monday . The stock traded as high as $11.79 and last traded at $11.6150. Approximately 254,848 shares were traded during trading, a decline of 65% from the average daily volume of 728,371 shares. The stock had previously closed at $10.55.

Analyst Ratings Changes

Several analysts recently issued reports on CLYM shares. Chardan Capital started coverage on shares of Climb Bio in a report on Tuesday, May 5th. They set a “buy” rating and a $22.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Climb Bio in a research report on Monday, April 20th. Guggenheim began coverage on shares of Climb Bio in a research note on Monday. They issued a “buy” rating and a $35.00 price objective on the stock. Wedbush raised their price objective on shares of Climb Bio from $15.00 to $17.00 and gave the stock an “outperform” rating in a research note on Friday, May 8th. Finally, Truist Financial started coverage on shares of Climb Bio in a research note on Tuesday, March 17th. They set a “buy” rating and a $17.00 target price for the company. Three equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $21.64.

Check Out Our Latest Analysis on Climb Bio

Climb Bio Stock Performance

The stock has a market capitalization of $648.79 million, a price-to-earnings ratio of -14.53 and a beta of 0.09. The company’s 50 day moving average is $9.55 and its 200 day moving average is $6.41.

Climb Bio (NASDAQ:CLYM – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.06. On average, equities research analysts anticipate that Climb Bio, Inc. will post -0.87 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of CLYM. AQR Capital Management LLC acquired a new position in shares of Climb Bio in the first quarter valued at $27,000. Vanguard Personalized Indexing Management LLC acquired a new position in shares of Climb Bio in the third quarter valued at $29,000. Qube Research & Technologies Ltd acquired a new position in shares of Climb Bio in the second quarter valued at $43,000. Virtu Financial LLC acquired a new position in shares of Climb Bio in the fourth quarter valued at $43,000. Finally, Blair William & Co. IL acquired a new position in shares of Climb Bio in the fourth quarter valued at $44,000. 69.76% of the stock is currently owned by institutional investors and hedge funds.

About Climb Bio

(Get Free Report)

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.